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Abstract 
The potent activator and chemoattractant for human neutrophils, neutrophil-activating peptide 2 (NAP-2), has been cloned and expressed in 
Escherichia coli. The protein has been purilied to homogeneity (> 98%) by a series of chromatographic techniques, including reversed phase HPLC. 
The biological activity of recombinant human NAP-2 (rhNAP-2), characterized by the induction of elastase release from human neutrophils, was 
found to be comparable to natural NAP-2. rhNAP-2 has been crystallized b 
group P222 with unit cell dimensions of a = 30.8 A, b = 39.5 A and c = 95.3 Iy 
the hanging drop vapor diffusion method. The crystals belong to space 
. A packing density of 3.8 A?Da with a solvent content of approximately 
68% is obtained when one molecule per asymmetric unit is assumed. The crystals were shown to diffract to beyond 2.0 A on a conventional X-ray 
source. They are stable to X-rays for several days and are thus suitable for high resolution structure determination. 
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1. Introduction 
Human neutrophils have been shown to exhibit a che- 
motactic response to neutrophil-activating peptide l/in- 
terleukin 8 (NAP-l/IL-g) [l] and also to the structurally 
homologous peptides melanoma growth-stimulatory ac- 
tivity (gro/MGSA) [2] and neutrophil-activating peptide 
2 (NAP-2) [3]. In addition to chemotaxis, NAP-l/IL-8 
has been characterized as an inducer of cytosolic free 
calcium changes, exocytosis and respiratory burst in neu- 
trophils, being indicative of a pro-inflammatory role in 
vivo. NAP-2 and gro/MGSA have been shown to exhibit 
broadly similar activities [2,4]. These common activities 
have been explained by the usage of one of the two IL-8 
receptors present on human neutrophils by all three pep- 
tides, while the other receptor recognizes only NAP-l/ 
IL-8 [5]. Despite their similar effects on neutrophils, 
NAP-l/IL-8 and NAP-2 differ in their mode of forma- 
tion and their cellular origin. NAP-l/IL-8 is produced 
and secreted by mononuclear phagocytes and a wide 
variety of tissue cells, as a result of transcriptional upreg- 
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ulation following stimulation by lipopolysaccharide, in- 
terleukin-1 and tumor necrosis factor. 
NAP-2 is produced in a completely different manner, 
being the proteolytic product of precursor peptides re- 
leased from platelet cl-granules [6], and as such is espe- 
cially worthy of further study. NAP-2 is the sequential 
cleavage product of platelet basic protein (PBP), tissue 
activating peptide III (CTAP-III) and /I-thromboglob- 
ulin @-TG)[7]. The carboxytermini of PBP, CTAP-III 
and /I-TG are identical, while the three molecules are 
shortened by 24, 15, and 11 residues, respectively, at the 
aminoterminus. In vitro, neutrophil-stimulating activity 
could be induced by the proteolytic action of human 
leukocyte cathepsin G and bovine pancreatic chymo- 
trypsin on CTAP-III, pointing to the involvement of 
serine proteases in vivo [7]. On the basis of its origin, 
NAP-2 has been proposed to be involved in vascular 
pathophysiological processes like thrombosis, arthero- 
sclerosis, and other inflammatory processes which are 
accompanied by platelet activation [7’J Inhibition of the 
interaction of NAP-2 with its receptor(s) by binding of 
small inhibitor molecules to the ligand or to the mem- 
brane receptor presents an attractive approach to che- 
motherapy of these deseases, and knowledge of the 3D 
structure of the NAP-2 molecule itself will greatly facili- 
tate the search for such inhibitors. 
NAP-2 consists of 70 amino acids (Fig. 1). It has a 
calculated molecular weight of 7,628 Da and a theoreti- 
cal isoelectric point of 8.7 [8]. NAP-2 and its precursors 
contain the four conserved cysteine residues characteris- 
tic of the a-chemokine family (CXC), the first two in this 
case spaced by methionine (Fig. 1). Two characteristic 
disulfide bonds are formed intramolecularly, linking 
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Cys-1 (aa 5) and Cys-3 (aa 31) as well as Cys-2 (aa 7) and 
Cys-4 (aa 47) [9]. These disulfide bonds were shown to 
be essential for biological acivity of NAP-l/IL-8 [lo]. 
The NAP-2 sequence contains potential sites for protein 
kinase C, casein kinase-II phosphorylation (Thr-39), 
N-myristoylation (Gly-28) and amidation (Asp-42). No 
N-glycosylation site is contained within the primary se- 
quence. Since chemically synthesized NAP-2 is biologi- 
cally fully active [8], these modifications do not seem to 
be important for neutrophil activation. In ultracentrifu- 
gation experiments /3-TG was identified as a tetramer 
which dissociates into fragments at low pH [ll]. No 
sedimentation experiments have been performed on 
NAP-2. The 3-dimensional structure of NAP-l/IL-8 has 
been well described and the active protein was found to 
consist of two identical subunits [12-171. Since the over- 
all homology of NAP-2 and NAP-l/IL-8 is 47%, a simi- 
lar molecular architecture is expected, including a 
dimeric quaternary structure for biologically active 
NAP-2. Moreover, the homology between the two che- 
mokines may assist in solving the structure of NAP-2 by 
Patterson search methods [ 181. 
2. Materials and methods 
All chemicals used in this study were p.a. grade and were used 
without further purification except PEG 8000 which was re-crystallyzed 
from isopropyl alcohol&ethyl ether. For polyacrylamide gel electro- 
phoresis commercially available Tris-Glycine gradient gels (420% and 
10-2796) from NOVEX (San Diego, USA) were used. Staining of the 
proteins was accomplished either by Coomassie brilliant blue (Bio-Rad, 
Richmond, USA) or/and by silver [19]. The protein concentration was 
determined either by measuring the optical density against a well char- 
acter&d standard of NAP-2 or by using the Pierce assay kit (Pierce, 
Rockford, Y3SA). Cation exchange FPL-chromatography was per- 
formed on a HR5/5 Mono-S column from Pharmacia (Pharmacia, 
Uppsala, Sweden). For preparative reversed phase HPLC a C-4 column 
(25 x 100 mm. 15 urn) on a Waters Delta Preu 3000 svstem (Millmore. 
&ford, USA) was used. For analytical rev&d phase HPLC a C-4 
column (Vydac, Hesperia, USA, Cat. 214TP10415) on a Beckman Sys- 
tem Gold (Beckman, Fullerton, USA) was used. Capillary electropho- 
301 
resis was performed on a Beckman P/ACE 2100 system (Beckman, 
Fullerton, USA). Concentration of the protein was done in Microsep 
Microconcentrators (Filtron, Northborough, USA). Screening of crys- 
tallization conditions was accomplished in Linbro (Flow Laboratories, 
Virginia, USA) multiwell tissue culture trays. Preliminary X-ray dif- 
fraction data were collected on an image plate system (MAR Research, 
Hamburg, Germany). 
3. Results and discussion 
Recombinant human NAP-2 (rhNAP-2) used in this 
study was expressed in E. coli as described previously for 
NAP-l/IL-8 [20]. After breaking the cells by ultrasonica- 
tion, the protein was extracted from the pellets by 6 M 
guanidinium-HCl containing 0.1 M Tris-HCl @H 7.2) 
and 2 mM EDTA. Centrifugation was followed by dial- 
ysis for 24 h of the supematant against 1 M GuHCl 
containing 50 mM Tris-HCl (pH 8.2), 2 mM reduced and 
0.2 mM oxidized glutathione to obtain the fully reduced 
form of the protein. After centrifugation, the clear super- 
natant was dialysed against 5% acetic acid and the gelat- 
inous precipitate was again removed by centrifugation. 
At this stage, the overall protein concentration was de- 
termined to be approximately 4 mg/ml. After buffer ex- 
change to 50 mM MES-NaOH (PH 5.6) containing 
5 mM NaN3 by dialysis, this solution was chromatogra- 
phed on a Mono-S HR5/5 FPLC column by eluting with 
a linear gradient (60 min) up to 1 M NaCl (detection at 
280 nm). rhNAP-2 elutes with 0.21 M NaCl. The 
rhNAP-2 containing fractions were pooled, lyophilized 
and dissolved in water containing 10% acetonitrile and 
0.1% trifluoroacetic acid. This solution was then loaded 
onto a C-4 reversed phase column. A linear gradient (120 
min) from lO-90% acetonitrile (containing 0.1% tri- 
fluoroacetic acid) was applied. rhNAP-2 eluted at 27% 
acetonitril (detection at 230 nm). The rhNAP-2 contain- 
ing fractions (purity > 98%) were pooled and then re- 
folded, under the same conditions as described above, on 
a Mono-S column. 
Fig. 1. Sequence of neutrophil-activating peptide 2. Filled circles mark amino acids homologous to NAP-l/IL-I. 
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Fig. 2. Capillary electrophoresis of rhNAP-2 (2hg) in 0.1 M Na-borate buffer f&H = 9.5) accomplished at 30°C and 20 kV. The protein was detected 
at 200 nm. 
Every step in the purification protocol was followed 
by polyacrylamide gel electrophoresis. Commercially 
purchased 420% or lO-27% gradient gels were run and 
stained by Coomassie blue reagent and/or by silver [19]. 
After preparative column chromatography the rhNAP-2 
containing fractions were analysed by reversed-phase 
HPLC (C-4) and compared to a NAP-2 standard. The 
retention time of rhNAP-2 was used to identify and the 
peak area was used to quantify the protein together with 
determining its overall amino acid content after total 
hydrolysis. The final purity was checked by capillary 
electrophoresis: rhNAP-2, suitable for crystallization ex- 
periments, migrated as a single peak (Fig. 2). The biolog- 
ical activity of rhNAP-2 was tested by a neutrophil elas- 
tase release assay (Fig. 3) [3]. The recombinant protein 
was found to be comparable to natural NAP-2, which is 
itself less active than NAP-l/IL-S. From 50 g wet E. coli 
cells 10 mg purified rhNAP-2 were obtained. The protein 
solution with a concentration of 2 mg/ml was frozen and 
could be stored at -20°C for at least 1 month. 
Immediately before crystallization experiments the 
protein solution was concentrated by micro seperation 
(molecular weight cut-off 3,000 Da) to 15 mg/ml. Dif- 
fraction quality crystals of rhNAP-2 were grown by the 
hanging drop vapor diffusion method using multiwell 
tissue culture trays [21]. Crystals were obtained in 5 ~1 
drops containing protein at 7.5 mg/ml and PEG 8000 at 
a concentration of 5-10% w/v. The drops were equili- 
brated at room temperature ither against 70-90% AS 
(of saturation) or against 3040% w/v PEG 8000. The 
buffers contained 5 mM 2-morpholinoethane-sulfonic 
acid (MES) and 3 mM NaN3 (pH 6.5). Small crystals of 
about 0.07 x 0.07 x 0.03 mm size were obtained within 
5-7 days. When these rhNAP-2 crystals were allowed to 
grow for about 2-4 weeks, slightly intercalated parallele- 
pipeds of about 0.3 x 0.3 x 0.1 mm size were obtained 
which were suitable for X-ray diffraction. The crystals 
were broken gently to obtain single-crystal fragments. 
rhNAP-2 crystals diffract to approximately 2 A on an 
image plate system. The space group was determined by 
precession photographs to be P222 with unit cell dimen- 
sions of a = 30.8 A, b = 39.5 A, and c = 95.3 A. The 
molecular mass weight of the protein (7,268 Da) as well 
as the volume of the unit cell suggest that the asymmetric 
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Fig. 3. Concentration-dependent i duction of elastase release (arbitrary 
fluorescence units) from human neutrophils by rhNAP-2 and rhNAP- 
l/IL-8. 
unit contains one monomer of rhNAP-2. According to 
Matthews [22] a crystal volume per unit of protein mo- 
lecular weight of 3.8 A3/Da has been computed. This 
corresponds to a solvent content of approximately 68%. 
Since the crystals are stable to long-term X-ray exposure 
(at least 48 h), they are suitable for high resolution struc- 
ture determination. 
In contrast to NAP-l/IL-8 crystals, which have a trig- 
onal space group when grown from different PEG’s and 
AS (space group P3,21), the shorter NAP-2 crystallized 
in an orthorombic space group. From the series of NAP- 
l/IL-8 mutants which were crystallized so far [17], an 
orthorombic space group could only be obtained from 
the C-&mitral truncated fragment l-66 (instead of 77 aa in 
the wild type protein). Wether the 50% reduced center 
to center distance between the two helices of the NAP-l/ 
IL-8 truncation mutant (l-66) will also be seen in NAP-2 
awaits clarification by solving the 3D structure. 
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